Stockreport

Century Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update

Century Therapeutics, Inc.  (IPSC) 
PDF Preclinical pipeline re-prioritization to focus on four potentially transformative programs to advance toward clinic, led by CNTY-308 in B-cell mediated autoimmune disea [Read more]